Evidence map›Paper›PMID 42818194›Full record

ArticlebioRxiv : the preprint server for biology2026

Bispecific GD2xB7-H3 Antibody Improves Tumor Targeting and Reduces Toxicity while Maintaining Efficacy for Neuroblastoma.

Amy K Erbe, Arika S Feils, Sabrina N Reinthaler, Alina Hampton, Zachary T Rosenkrans, Yadira Guevara, Mildred Felder, Jessica Wiwczar, Daniel J Gerhardt, Mark Bercher and 20 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Amy K ErbeDept. of Human Oncology, University of Wisconsin, Madison, WI, USA.
Arika S FeilsDept. of Human Oncology, University of Wisconsin, Madison, WI, USA.
Sabrina N ReinthalerDept. of Pediatrics, University of Wisconsin, Madison, WI, USA.
Alina HamptonDept. of Human Oncology, University of Wisconsin, Madison, WI, USA.
Zachary T RosenkransDept. of Medical Physics, University of Wisconsin, Madison, WI, USA.
Yadira GuevaraDept. of Medical Physics, University of Wisconsin, Madison, WI, USA.
Mildred FelderDept. of Human Oncology, University of Wisconsin, Madison, WI, USA.
Jessica WiwczarInvenra Inc., Madison WI, USA.
Daniel J GerhardtInvenra Inc., Madison WI, USA.
Mark BercherInvenra Inc., Madison WI, USA.
Belinda WenkeInvenra Inc., Madison WI, USA.
Callie HaertleDept. of Human Oncology, University of Wisconsin, Madison, WI, USA.
Mackenzie HeckDept. of Human Oncology, University of Wisconsin, Madison, WI, USA.
Kaia HeimstreetDept. of Human Oncology, University of Wisconsin, Madison, WI, USA.
Elizabeth FrankelDept. of Human Oncology, University of Wisconsin, Madison, WI, USA.
Megan NielsenDept. of Human Oncology, University of Wisconsin, Madison, WI, USA.
Dan SpiegelmanDept. of Human Oncology, University of Wisconsin, Madison, WI, USA.
Noah TsarovskyDept. of Human Oncology, University of Wisconsin, Madison, WI, USA.
Jen ZaborekDept. of Biostatistics and Medical Informatics, Madison, WI, USA.
Alexander L RakhmilevichDept. of Human Oncology, University of Wisconsin, Madison, WI, USA.
Jacquelyn A HankDept. of Human Oncology, University of Wisconsin, Madison, WI, USA.
Eduardo Aluicio-SarduyDept. of Medical Physics, University of Wisconsin, Madison, WI, USA.
Jonathan W EngleDept. of Medical Physics, University of Wisconsin, Madison, WI, USA.
Jonathan H DavisInvenra Inc., Madison WI, USA.
Bryan GlaserInvenra Inc., Madison WI, USA.
Vladimir SubbotinDept. of Human Oncology, University of Wisconsin, Madison, WI, USA.
Roland GreenInvenra Inc., Madison WI, USA.
Reinier HernandezDept. of Medical Physics, University of Wisconsin, Madison, WI, USA.
Bonnie HammerInvenra Inc., Madison WI, USA.
Paul M SondelDept. of Human Oncology, University of Wisconsin, Madison, WI, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The current treatment regimen for neuroblastoma involves immunotherapy, including a monoclonal antibody that recognizes disialoganglioside (GD2), expressed at high levels on neuroblastoma. GD2 is not present on most normal tissues except for nerves. Thus, anti-GD2 antibody treatment causes substantial, dose-limiting neuropathic pain. B7-H3 is overexpressed on multiple tumor types, including neuroblastoma, and is largely absent on nerves and other normal tissues. We designed a bispecific antibody (bsAb) that requires simultaneous binding of these two tumor antigens to achieve tight binding of tumor cells. Our preclinical research shows that, compared with a monospecific anti-GD2 antibody, the GD2×B7-H3 bsAb has improved tumor specificity, comparable antitumor efficacy, and reduced nerve binding and pain-associated toxicity. Since this bsAb does not bind to nerves, it may permit more tolerable and sustained treatment schedules than are currently feasible with monospecific anti-GD2 antibodies. In addition, its enhanced tumor specificity may support future development as a targeted delivery platform for antibody-drug conjugates or other payload-based therapies, potentially improving both efficacy and quality of life for patients with neuroblastoma.

Identifiers

PMID42818194
PMCPMC13622138

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.